BioSpace News Archive

Givosiran Associated with Substantial and Sustained Lowering of Neurotoxic Heme Synthesis Intermediates Implicated in Acute Intermittent Porphyria

Leidos announced the company will showcase its solutions for hospitals, health systems, and government customers during the 2019 Healthcare Information and Management Systems Society conference February 11-15 in Orlando.

One of the most important roles we have as a public health agency is educating patients and health care providers about both the benefits and risks of medical products, including breast implants.

Taro Pharmaceutical Industries Ltd. provided unaudited financial results for the three and nine months ended December 31, 2018.

Alector, Inc. announced the pricing of its initial public offering of 9,250,000 shares of common stock to the public at $19.00 per share.

FSD Pharma Inc. announced that its Board of Directors has concluded a strategic assessment of the Company and has implemented changes in leadership and business practices to optimize operations.

An innovative and differentiated tooling design and processing technology called PtFS (Production to Functional Specification), from UK-based Surface Generation, has been chosen by Victrex as it seeks to bring enhanced manufacturing effectiveness to its parts-based ‘mega-programs’ and to OEM, Tier 1s, and the molding community.

Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose therapeutics utilizing its patented piezo-print delivery technology, today announced that the U.S. Food and Drug Administration (FDA) has accepted the Company’s Investigational New Drug (IND) application to initiate the CHAPERONE study - the Company’s Phase III registration trial of MicroPine to reduce the progression of myopia in children.

Clinigen Group plc (AIM: CLIN, ‘Clinigen’ or the ‘Group’), the global pharmaceutical and services company, has appointed Nick Keher Group Chief Financial Officer with effect from 19 March 2019. He will replace Martin Abell, who has resigned and leaves the business on 31 March 2019.

Aigenpulse Ltd., (Aigenpulse), a big data technology company which specialises in structuring, integrating and deriving meaning from large, disparate data assets, today announced it has achieved certification to the internationally recognised standards ISO 9001:2015 and ISO 27001:2013.